We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the ...

It is unclear what the company intends to charge for the vials, the report said. ・Unlike Novo, Eli Lilly and Company already ...

Novo and Lilly are locked in a tightening fight in the obesity-drug market, with Novo trying to win back its crown after a ...

New data shows Wegovy pill uptake: 36% are new to GLP-1s, with many switching from injectable versions. Read more here.

The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.

Despite their huge popularity, GLP-1 injury lawsuits citing the drugs as a cause for a host of severe GI issues and even ...

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two ...

When Mike Doustdar started as a summer employee making copies at Novo Nordisk—a teenager living in Austria after fleeing unrest in his home country of Iran at 12—he never imagined he would remain at ...

Joe Budden discusses using Zepbound, fitness changes, and health awareness during an appearance on 'Club Shay Shay.' ...

Although the 2026 Novartis ad showed up 75th on EDO’s ranking, TV ad measurement company iSpot separately pinned a likeability score of 643 on the spot, determining it to be the highest-scoring of its ...

Eli Lilly's fourth-quarter revenue rose by 43%, largely a result of its impressive GLP-1 products. Sales from its GLP-1 drugs ...

Kailera CEO Ron Renaud claimed the weight loss effects and safety profile observed in the study suggest its therapy could ...